Continuous Glucose Monitoring

CGM has proven to be the best outpatient glycemic management system for reducing A1C. People with type 1 diabetes have experienced an average A1C reduction of 1.3%1

What is (CGM) Continuous Glucose Monitoring?

A CGM provides continuous insight into glucose levels throughout the day and night. The device displays information about glucose speed and direction providing users additional information to help better manage their diabetes. It automatically checks your glucose levels every 5 minutes and can display your glucose numbers in real-time on a compatible smart device or receiver. Some CGM’s feature a convenient application that is accessible to mobile devices, such as the iPhone, Apple Watch, and Android devices.

A CGM System consists of three basic parts:

  1. Sensor – A small sensor is inserted just beneath the skin and measures your interstitial fluid for glucose values. Typically, a sensor is approved to remain underneath the skin for up to 7-10 days.
  2. Transmitter – A small wearable that is affixed to the top of the sensor and sends glucose data wirelessly to your compatible smart device or receiver.
  3. Display device - A compatible smart device or receiver will have a display screen where you receive your current glucose number and the ability to review past and present glucose trends with your physician for better diabetes management.

Benefits of a CGM

  • A1c Reduction: CGM has proven to be the best outpatient glycemic management system for reducing A1C. People with type 1 diabetes have experienced an average A1C reduction of 1.3%*1.
  • Reduced Hypoglycemia: Not only can CGM reduce A1C, numerous studies have shown it can also decrease time spent in hypoglycemia1-3
  • Alerts and Alarms: CGM Systems are equipped with alerts and alarms that notify you of approaching highs and lows
  • Real-time glucose information: CGM provides real-time information about your glucose level speed and direction (high or low), so you have more insight for proactively managing your diabetes.

Continuous Glucose Monitoring Products


Dexcom CGM System

The Dexcom G6 eliminates fingersticks for calibration, diabetes treatment decisions and diabetes management*.

  • The Dexcom G6 CGM System can now be used in place of fingerstick testing for treatment decisions*.
  • The Dexcom CGM System is approved for ages 2 years and older on the abdomen and lower back. For 18 and over, the Dexcom CGM is approved for the abdomen.
  • The Dexcom CGM is compatible with iOS and Android platforms which allow glucose readings on a compatible smart device†.
  • The Dexcom also has a Share feature which allows you to share your glucose readings with up to five individuals‡. By downloading the Dexcom Follow® app, followers can view your real-time glucose data directly from their smart device giving you the circle of support you need. Visit for more information.

Hear from users just like you: Dexcom Warriors


FreeStyle Libre 2 System

  • FreeStyle Libre 2 is a continuous glucose monitoring system now FDA cleared for adults and children with diabetes ages 4 years and above.
  • Now with optional, real-time glucose alarms that notify you if you go too low or too high*.
  • Unsurpassed 14 day accuracy for adults and children with diabetes.
  • You can easily check your glucose levels with a painless one second scan instead of a fingerstick†

*Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.
† Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.
References: 1. FreeStyle Libre 2 User's Manual 2. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicentre, open-label randomised controlled trial. Diabetes Ther. 2017;8(1):55-73.

FreeStyle Libre 2 system:
The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older*

WARNINGS/LIMITATIONS*: The System must not be used with automated insulin dosing (AID) systems, including closed loop and insulin suspend systems. Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment. Do not take high doses of vitamin C (more than 500 mg per day), as this may falsely raise your Sensor readings. Failure to use the System according to the instructions for use may result in missing a severe low blood glucose or high blood glucose event and/or making a treatment decision that may result in injury. If glucose alarms and readings from the System do not match symptoms or expectations, use a fingerstick blood glucose value to make diabetes treatment decisions. Seek medical attention when appropriate and contact Abbott Toll Free (855-632-8658) or visit* for detailed indications for use and safety information.

*For full indications for use and safety information, see more here.

MiniMed670G image

Medtronic 670G

Medtronic Minimed 670G system is the first Closed Loop System; it is accompanied with a new Guardian sensor which will automatically stop and restart insulin based on your preset target blood glucose levels. The pump is able to adjust your basal insulin every 5 minutes to keep you in your target range 24 hours per day.

*MDI patients with baseline A1C ≥ 8.5%
*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
†Click here for a list of compatible smart devices
‡Do not make treatment decisions based on share and follow readings. Always confirm with your compatible smart device or Dexcom receiver.
1 Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes, N Engl J Med. 2008: 359(14); 1464-1476.
2 Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
3 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The diamond randomized clinical trial. JAMA. 2017;317(4):371-378. doi:10.1001/jama.2016.19975.